Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Purple Biotech Ltd. - American Depositary Shares (NQ:PPBT)

1.292 +0.042 (+3.37%)
Delayed Quote Updated: 1:27 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Purple Biotech Ltd. - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Peraso (NASDAQ: PRSO) Eyes Military Robotics as U.S. Army Advances Autonomous Fleet
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Regains Compliance with Nasdaq
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces CEO Transition
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Plan to Implement ADS Ratio Change
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Pricing of Up To $18 Million Public Offering
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.